Stem Cell Therapy for Peyronie's Disease

Peyronie's disease — the buildup of fibrous scar tissue (plaque) inside the penis that causes curvature, pain, and shortening — has become one of the more active areas of regenerative urology research. Small human studies using adipose-derived and placental stem cells have shown genuinely encouraging signals: shrinking plaques, eased curvature, and real relief in the psychological distress this condition causes. But no stem cell product has been proven in a large controlled trial or approved by the FDA for this use, and the field's most rigorous study to date fell short of its main curvature-reduction goal. This article lays out what the evidence actually shows, who might reasonably consider it, and where things stand today.

How It's Thought to Work

Peyronie's plaques form when the tunica albuginea — the fibrous sheath around the erectile tissue — heals abnormally after injury, laying down excess collagen and scar tissue. Mesenchymal stem cells, whether harvested from a patient's own fat (adipose-derived), bone marrow, or placental tissue, are of interest here because of their antifibrotic and anti-inflammatory signaling properties. In animal models, injecting these cells directly into the plaque appears to interrupt the scarring process and, in some studies, preserve erectile tissue function alongside it. The appeal is straightforward: rather than just cutting away or chemically dissolving existing scar tissue, the goal is to change the underlying repair process itself.

What the Evidence Shows

The most encouraging early human data came from a small 2015 study of five men with Peyronie's disease treated with placental matrix-derived mesenchymal stem cells, described by its authors as the first published human use of stem cells for this condition (Levine et al., J Am Osteopath Assoc, 2015). Notably, seven of ten treated plaques disappeared completely by three months, and blood flow to the penis improved significantly — a genuinely promising early signal, even though the study was too small and short to establish reliable efficacy on its own.

The largest and most rigorous trial to date is the 2025 Danish "Straight @head" pilot study, which treated 22 men with a single injection of their own adipose-derived regenerative cells and followed them for a full year (Wiborg et al., European Urology Open Science, 2025). The safety picture here was reassuring: no serious adverse events, and only mild, self-resolving side effects like abdominal soreness or bruising at the fat-harvest site. Plaque size shrank substantially, from a mean of 538 mm³ to 251 mm³ (statistically significant), and men reported a meaningful drop in the psychological distress associated with the condition. A combined "primary curvature" measure also improved significantly, by 12.3 degrees.

That said, the trial's own pre-set benchmark — a 17-degree reduction in dorsal or lateral curvature — was not met: dorsal curvature dropped 6.2 degrees and lateral curvature 8.5 degrees, neither reaching statistical significance, and only 27% of men hit the 17-degree target in either direction. Two independent review articles from 2016 and 2017 (Sangkum et al.; Yafi et al.) reach a similar overall verdict: adipose-derived stem cells look feasible and safe based on preclinical and very early human work, but both explicitly call for larger, controlled human trials before the therapy can be considered established.

Who Might Be a Candidate

• Men with chronic-phase (stable, non-worsening) Peyronie's disease who are considering enrollment in a legitimate clinical trial rather than a commercial "stem cell clinic" offering
• Men who have already discussed FDA-approved options — such as collagenase clostridium histolyticum (Xiaflex) injections, penile traction therapy, or surgical correction — with a urologist
• Men primarily interested in plaque softening or the psychological burden of the condition, where early data is more consistent, rather than guaranteed correction of curvature
• Anyone should first confirm a clinic is operating under an FDA-cleared investigational protocol, not marketing an unapproved, unproven procedure directly to patients

Bottom Line

Stem cell therapy for Peyronie's disease is a real and active area of research with some genuinely hopeful early results — smaller plaques, less distress, and a strong safety record across the studies so far. It is not, however, an FDA-approved treatment, and the best-designed trial to date did not reach its primary curvature-reduction goal. For now, the proven, approved options remain collagenase injections (Xiaflex), traction therapy, and surgery; stem cell approaches belong in the context of a clinical trial, not a routine clinic visit, until larger controlled studies confirm what these early signals suggest.